LT4339B - Melatonino panaudojimas gamyboje vaistų, skirtų gydyti ligonius, kenčiančius nuo palinkimo į vaistus - Google Patents

Melatonino panaudojimas gamyboje vaistų, skirtų gydyti ligonius, kenčiančius nuo palinkimo į vaistus Download PDF

Info

Publication number
LT4339B
LT4339B LT97-135A LT97135A LT4339B LT 4339 B LT4339 B LT 4339B LT 97135 A LT97135 A LT 97135A LT 4339 B LT4339 B LT 4339B
Authority
LT
Lithuania
Prior art keywords
melatonin
benzodiazepine
medicament
treatment
benzodiazepine drug
Prior art date
Application number
LT97-135A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT97135A (en
Inventor
Nava Zisapel
Original Assignee
Neurim Pharmaceuticals (1991) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharmaceuticals (1991) Ltd filed Critical Neurim Pharmaceuticals (1991) Ltd
Publication of LT97135A publication Critical patent/LT97135A/xx
Publication of LT4339B publication Critical patent/LT4339B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LT97-135A 1995-02-01 1997-08-01 Melatonino panaudojimas gamyboje vaistų, skirtų gydyti ligonius, kenčiančius nuo palinkimo į vaistus LT4339B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/381,535 US6469044B1 (en) 1995-02-01 1995-02-01 Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies

Publications (2)

Publication Number Publication Date
LT97135A LT97135A (en) 1997-12-29
LT4339B true LT4339B (lt) 1998-05-25

Family

ID=23505399

Family Applications (1)

Application Number Title Priority Date Filing Date
LT97-135A LT4339B (lt) 1995-02-01 1997-08-01 Melatonino panaudojimas gamyboje vaistų, skirtų gydyti ligonius, kenčiančius nuo palinkimo į vaistus

Country Status (13)

Country Link
US (3) US6469044B1 (ro)
EP (1) EP0724878B1 (ro)
KR (1) KR100425045B1 (ro)
AR (1) AR003921A1 (ro)
DE (1) DE69512760T2 (ro)
ES (1) ES2139842T3 (ro)
HK (1) HK1001218A1 (ro)
IL (1) IL114296A (ro)
LT (1) LT4339B (ro)
RO (1) RO116771B1 (ro)
RU (1) RU2182001C2 (ro)
UA (1) UA63878C2 (ro)
ZA (1) ZA96548B (ro)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469044B1 (en) * 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
IL130171A (en) * 1999-05-27 2004-06-01 Neurim Pharma 1991 Melatonin for use in preventing and treating tardive dyskinesia, pharmaceutical preparations containing it and its use in the manufacture of medicines
IL144900A (en) * 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
US6998112B2 (en) * 2003-03-18 2006-02-14 Arthur Zuckerman Sleep inducing toothpaste made with natural herbs and a natural hormone
WO2005082143A1 (en) * 2004-02-20 2005-09-09 Lifescape Biosciences Incorporated Compositions and methods for sleep regulation
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
TR201808978T4 (tr) 2011-02-11 2018-07-23 Zx Pharma Llc Çok partiküllü l-mentol formülasyonları ve ilgili yöntemler.
RU2488388C1 (ru) 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
UA107653U (uk) 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
WO2014175917A1 (en) 2013-04-23 2014-10-30 Zx Pharma, Llc Multiparticulate-menthol formulations and related methods
EP3777842A1 (en) 2016-10-31 2021-02-17 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
WO2024079125A1 (en) 2022-10-14 2024-04-18 Société des Produits Nestlé S.A. Sustained release melatonin compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0513702A2 (en) 1991-05-13 1992-11-19 I.F.L.O. ISTITUTO FARMACOLOGICO LOMBARDO S.A.S. di Giorgio & Aldo Laguzzi & C. Melatonin derivaties for use in the therapy of sleep disorders and in pre-anaesthetic medication
EP0518468A1 (en) 1991-05-09 1992-12-16 Neurim Pharmaceuticals (1991) Limited Melatonin containing compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600723A (en) 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
AU601736B2 (en) 1986-05-23 1990-09-20 Sanofi Sante Nutrition Animale Sa Coated veterinary implants
US4800087A (en) 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
US5242941A (en) 1990-12-04 1993-09-07 State Of Oregon Methods of treating circadian rhythm disorders
US5449683A (en) 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
US6469044B1 (en) * 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0518468A1 (en) 1991-05-09 1992-12-16 Neurim Pharmaceuticals (1991) Limited Melatonin containing compositions
EP0513702A2 (en) 1991-05-13 1992-11-19 I.F.L.O. ISTITUTO FARMACOLOGICO LOMBARDO S.A.S. di Giorgio & Aldo Laguzzi & C. Melatonin derivaties for use in the therapy of sleep disorders and in pre-anaesthetic medication

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ACUNA CASTROVIEJO D ET AL.: "Diurnal variations of benzodiazepine binding in rat cerebral cortex: disruption by pinealectomy", J PINEAL RES, 1986, pages 101 - 102
CARDINALI DP ET AL.: "Functional links between benzodiazepine and GABA receptors and pineal activity", ADV BIOCHEM PSYCHOPHARMACOL., 1986, pages 155 - 164, XP000571409
D. GREENBLAT, R. SHADER: "Greenblatt DJ, Shader RI. Dependence, tolerance, and addiction to benzodiazepines: clinical and pharmacokinetic considerations", DRUG METABOLISM REVIEWS, 1978, pages 13 - 28
GUARDIOLA-LEMAîTRE, B. ET AL.: "Combined effects of diazepam and melatonin in two tests for anxiolytic activity in the mouse", PHARMACOL. BIOCHEM. BEHAV., 1992, pages 405 - 408, XP023807215, DOI: doi:10.1016/0091-3057(92)90118-Y
I. M. MCINTYRE: "Suppression of plasma melatonin by a single dose of the benzodiazepine alprazolan in humans", BIOL. PSYCHIAT., 1988, pages 105 - 108
KABUTO M, NAMURA I, SAITOH Y.: "Nocturnal enhancement of plasma melatonin could be suppressed by benzodiazepines in humans", ENDOCRINOLOGIA JAPONICA, 1986, pages 405 - 414
NILES L.P., PICKERING D.S., ARCISZEWSKI M.A: "Effects of chronic melatonin administration on gaba and diazepam binding in rat brain", J. NEURAL TRANSM., 1987, pages 117 - 124, XP000571404, DOI: doi:10.1007/BF01252513
Y. ANIS, I. NIR, U. SCHMIDT, N. ZISAPEL: "Modification by oxazepam of the diurnal variations in brain125I-melatonin binding sites in sham-operated and pinealectomized rats", JOURNAL OF NEURAL TRANSMISSION, 1992, pages 155 - 166, XP000571405, DOI: doi:10.1007/BF01250668

Also Published As

Publication number Publication date
LT97135A (en) 1997-12-29
HK1001218A1 (en) 1998-06-05
IL114296A (en) 1999-10-28
US6833383B2 (en) 2004-12-21
KR19980701640A (ko) 1998-06-25
ZA96548B (en) 1996-08-14
RO116771B1 (ro) 2001-06-29
EP0724878A2 (en) 1996-08-07
US6469044B1 (en) 2002-10-22
EP0724878A3 (ro) 1996-08-21
UA63878C2 (en) 2004-02-16
AR003921A1 (es) 1998-09-30
RU2182001C2 (ru) 2002-05-10
ES2139842T3 (es) 2000-02-16
US20030040539A1 (en) 2003-02-27
DE69512760D1 (de) 1999-11-18
EP0724878B1 (en) 1999-10-13
IL114296A0 (en) 1995-10-31
KR100425045B1 (ko) 2004-09-01
US20020156121A1 (en) 2002-10-24
DE69512760T2 (de) 2000-05-31

Similar Documents

Publication Publication Date Title
LT4339B (lt) Melatonino panaudojimas gamyboje vaistų, skirtų gydyti ligonius, kenčiančius nuo palinkimo į vaistus
US8728511B2 (en) Method of treatment comprising administering controlled release melatonin
Söderpalm et al. Anticonflict and rotarod impairing effects of alprazolam and diazepam in rat after acute and subchronic administration
AU695366B2 (en) Use of melatonin for treating patients suffering from drug addiction
Hurst et al. Zaleplon.
US6344487B1 (en) Treatment of insomnia
Luboshizsky et al. Sleep-inducing effects of exogenous melatonin administration
CA2211839C (en) Use of melatonin for treating patients suffering from drug addiction
Eison Lack of withdrawal signs of dependence following cessation of treatment or Ro-15, 1788 administration to rats chronically treated with buspirone
MXPA97005856A (en) Use of melatonine in the manufacture of unmedicament to deal with addiction to dro
Briley et al. Pasteur euroconference on future therapies for an anxious world
Newswire Eisai and Purdue Pharma Present Efficacy and Safety Data from Second Pivotal Phase 3 Study
ZA200206228B (en) Method and formulation for treating resistance to antihypertensives and related conditions.

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20070129